BACKGROUND: The burden of chronic diseases such as type 2 diabetes (T2D) and associated comorbidities increases with ageing, making the elderly more vulnerable to potential side effects of medical treatment. Information about the effect of antihyperglycemic therapy on cardiovascular (CV) events in the elderly is limited. Liraglutide reduced the risk of CV events in the LEADER trial compared with placebo, and this post hoc analysis assesses risk of CV events and all-cause mortality in elderly patients with T2D.
METHODS: In the LEADER trial, 9,340 patients with T2D at high risk for CV events were randomized 1:1 to liraglutide or placebo, both on top of standard of care, and followed for up to 5 years. The primary composite outcome was defined as time to first occurrence of death from CV causes, non-fatal myocardial infarction (MI), or non-fatal stroke. Secondary outcomes included the expanded composite outcome and all-cause mortality. In this analysis, outcomes were assessed in patients aged ≥75 years.
RESULTS: Among those aged ≥75 years, baseline characteristics were well matched between treatment arms (N=418 for both treatment arms). Compared with placebo, liraglutide significantly reduced the risk of the primary composite outcome, expanded composite outcome, non-fatal MI, coronary revascularization, death from any cause and death from non-CV causes (Table).
CONCLUSION: In the LEADER trial, liraglutide treatment reduced the risk of CV events and all-cause mortality in elderly patients with T2D.